Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy.
Clicks: 244
ID: 83107
2020
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Star Article
75.1
/100
237 views
192 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Despite significant effort devoted to developing new treatments and procedures, cardiac disease is still one of the leading causes of death in the world. The loss of myocytes due to ischemic injury remains a major therapeutic challenge. However, cell-based therapy to repair the injured heart has shown significant promise in basic and translation research and in clinical trials. Embryonic stem cells have been successfully used to improve cardiac outcomes. Unfortunately, treatment with these cells is complicated by ethical and legal issues. Recent progress in developing induced pluripotent stem cells (iPSCs) using non-viral vectors has made it possible to derive cardiomyocytes for therapy. This review will focus on these non-integration-based approaches for reprogramming and their therapeutic advantages for cardiovascular medicine.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (119 words).
Try re-searching for a better abstract.
| Reference Key |
panda2020nonviraldifferentiation
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Panda, Arunima;Gurusamy, Narasimman;Rajasingh, Sheeja;Carter, Hannah-Kaye;Thomas, Edwin L;Rajasingh, Johnson; |
| Journal | differentiation; research in biological diversity |
| Year | 2020 |
| DOI |
S0301-4681(20)30001-3
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.